drugset / Trial / NCT01058642

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642

Phase 2 Terminated 41 enrolled Merck & Co., Inc. Pfizer · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the analgesic efficacy of ADL5747 in participants with postherpetic neuralgia (PHN). The secondary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of ADL5747.

Timeline

Start
2010-01
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ADL5747 Small molecule 150 mg Oral
Comparator Pregabalin Small molecule 150 mg Oral